Interviews & Opinion

The Biggest Things About Schedule III You Haven’t Thought Of

Brian Vicente of Vicente LLP talks Schedule III with Cannabis Business Times

Closing the Hemp Loophole Does Not Mean Your Business Has to Close (Opinion)

Potential changes to the 2018 Farm Bill’s definition of hemp, if enacted, mean businesses will have one year to adapt their operations.

Cannabis Workforce Solutions: How Licensed Cultivators, Dispensaries Benefit From Industry-Education Alliances (Opinion)

As the cannabis industry matures, the integration of targeted workforce and business development training will be essential.

The Race to Nowhere: How Chasing Potency Undermines Cannabis Quality (Opinion)

The current THC labeling system is misleading, and consumers deserve more accurate, meaningful information.

German Cannabis Market Establishes Foundation for Global Industry Expansion (Op-Ed)

The fact that legal cannabis in Germany is more affordable than the illegal market is revolutionary for the global cannabis industry to date.

Innovating for the Benefit of Patients in Medical Cannabis (Opinion)

Poor bioavailability formulations in orally delivered medical cannabis have left an innovation gap for patients.

Rescheduling Update: How Long Is the Wait? What’s Next?

Government affairs and policy expert David Mangone tells us what we can expect from the DEA as weeks pass following the public comment period, including insights on the DEA’s final review and if a hearing is likely to be granted.

Mitch Meyers on How to 'Manage the Chaos' in Cannabis

The founder of Missouri's BeLeaf Medical says women are 'uniquely suited' to be leaders in the male-dominated industry.

7 Takeaways From the Feds' Cannabis Rescheduling Recommendation

Attorney Jonathan Havens outlines what stood out for him most after reviewing the 252-page document released by the U.S. Department of Health & Human Services.

Opinion: The Cannabis Industry Must Prioritize Worker Safety, Invest in PPE

The hazards associated with cannabis production are well-documented, and it's time for the industry to step up and prioritize the health and safety of its employees.

Federal Government Continues to Withhold Key Cannabis Scheduling Recommendation Letter Despite FOIA Requests, Lawsuit

After nearly three months and multiple Freedom of Information Act requests, the U.S. Department of Health and Human Services still has not publicly confirmed that it recommended cannabis be reclassified as a Schedule III controlled substance. One attorney who filed a lawsuit to obtain the letter calls the situation "asinine" and "profoundly disappointing."

A Positive Sign For Schedule III

In Vienna, a U.S. state department legal adviser champions member-state discretion over domestic drug policy, potentially removing the obstacle the Single Convention drug treaty could pose to cannabis reform.

Page 1 of 51

Next Page